• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Merit Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    2/25/25 4:18:44 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care
    Get the next $MMSI alert in real time by email
    0000856982falseMERIT MEDICAL SYSTEMS INC00008569822025-02-252025-02-25

    ​

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C.  20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    ​

    Date of Report (date of earliest event reported): February 25, 2025

    ​

    Graphic

    ​

    Merit Medical Systems, Inc.

    (Exact name of registrant as specified in its charter)

    ​

    ​

    ​

    ​

    ​

    ​

    Utah

        

    0-18592

        

    87-0447695

    (State or other jurisdiction of

    ​

    (Commission

    ​

    (I.R.S. Employer

    incorporation or organization)

    ​

    File Number)

    ​

    Identification No.)

    ​

    ​

    ​

    ​

    1600 West Merit Parkway

        

    ​

    South Jordan, Utah

    ​

    84095

    (Address of principal executive offices)

    ​

    (Zip Code)

    ​

    (801) 253-1600

    (Registrant's telephone number, including area code)

    ​

    N/A

    (Former name or former address, if changed since last report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ​

    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ​

    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ​

    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

        

    Trading Symbol(s)

        

    Name of each exchange on which registered

    Common Stock, no par value

    ​

    MMSI

    ​

    NASDAQ Global Select Market System

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    ​

    Emerging growth company        ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    ​

    Item 2.02.  Results of Operations and Financial Condition.

    ​

    On February 25, 2025, Merit Medical Systems, Inc. (“Merit”) issued a press release announcing its operating and financial results for the quarter and year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

    ​

    ​

    Item 7.01. Regulation FD Disclosure.

    ​

    On February 25, 2025, Merit is conducting a conference call to discuss its operating and financial results for the quarter and year ended December 31, 2024. A live webcast and slide presentation will also be available for the conference call on the Merit’s website. A copy of the slide presentation is furnished as Exhibit 99.2 to this report and incorporated herein by reference.

    ​

    The information contained in Item 2.02 and Item 7.01 of this Current Report on Form 8-K (including the exhibits attached hereto) is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by Merit under the Securities Act of 1933, as amended, or the Exchange Act.

    ​

    In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“GAAP”), Merit is disclosing non-GAAP financial information in both the press release announcing its operating and financial results and the conference call presentation. Reconciliations of certain of these non-GAAP financial measures to the comparable GAAP financial measures are included in the press release and conference call presentation attached as Exhibit 99.1 and 99.2, respectively, to this report. Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of items such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain severance expenses, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reliably predict the impact of these items and Merit believes inclusion of a reconciliation of these forward-looking non-GAAP figures to their GAAP counterparts could be confusing to investors or cause undue reliance.

    ​

    ​

    Item 9.01.  Financial Statements and Exhibits.

    ​

    (d)            Exhibits

    EXHIBIT NUMBER

        

    DESCRIPTION

    ​

    ​

    ​

    99.1

    ​

    Press Release, dated February 25, 2025, entitled “Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Issues Fiscal Year 2025 Guidance” including unaudited financial information.

    99.2

    ​

    Conference Call Presentation.

    104

    ​

    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

    ​

    ​

    ​

    2

    ​

    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    MERIT MEDICAL SYSTEMS, INC.

    ​

    ​

    ​

    ​

    ​

    ​

    Date: February 25, 2025

    By:

    /s/ Brian G. Lloyd

    ​

    ​

    Brian G. Lloyd

    ​

    ​

    Chief Legal Officer and Corporate Secretary

    ​

    ​

    ​

    ​

    3

    Get the next $MMSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MMSI

    DatePrice TargetRatingAnalyst
    3/28/2025$120.00Overweight
    Analyst
    12/11/2024$103.00 → $120.00Equal Weight → Overweight
    Wells Fargo
    6/28/2024$96.00Outperform
    Robert W. Baird
    4/11/2024$88.00Buy
    CL King
    2/7/2024$87.00Neutral
    BofA Securities
    12/21/2023$100.00Hold → Buy
    Canaccord Genuity
    12/20/2022$73.00 → $72.00Buy → Hold
    Canaccord Genuity
    2/25/2022$73.00 → $72.00Outperform
    Raymond James
    More analyst ratings

    $MMSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst initiated coverage on Merit Medical with a new price target

      Analyst initiated coverage of Merit Medical with a rating of Overweight and set a new price target of $120.00

      3/28/25 8:20:21 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Merit Medical from Equal Weight to Overweight and set a new price target of $120.00 from $103.00 previously

      12/11/24 7:56:29 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Robert W. Baird initiated coverage on Merit Medical with a new price target

      Robert W. Baird initiated coverage of Merit Medical with a rating of Outperform and set a new price target of $96.00

      6/28/24 8:04:44 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF OPERATING OFFICER Peterson Neil exercised 5,000 shares at a strike of $54.40 and sold $522,650 worth of shares (5,000 units at $104.53) (SEC Form 4)

      4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

      4/2/25 4:54:46 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • CHIEF LEGAL OFFICER, SECRETARY Lloyd Brian G. gifted 4,700 shares, decreasing direct ownership by 12% to 34,245 units (SEC Form 4)

      4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

      3/14/25 11:45:46 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • CHIEF HUMAN RESOURCES OFFICER Voigt Michel James gifted 620 shares, decreasing direct ownership by 3% to 21,779 units (SEC Form 4)

      4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

      3/6/25 5:41:11 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis

      The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.Approval was supported by superior 12-month target lesion primary patency (70.1%) and access circuit primary patency (58.1%) in the randomized arm of the trial. SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulatory approval from Health Canada. With this approval, Merit intends to begin immediate commercialization of the device throughout Canada with devices shipped from Merit's Toronto distribution center. Lo

      5/6/25 9:25:00 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial

      SOUTH JORDAN, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced that the 12-month results from the single-arm cohort of the WAVE trial were presented at the annual Charing Cross Symposium held in London, England, on April 23, 2025, during the Vascular Access Masterclass session. Following the scientific podium presentation, results were presented during a Merit-sponsored symposium. The single-arm cohort of the WAVE trial included 112 patients with an AVG who were treated with the WRAPSODY CIE device. The primary efficacy measure, 6-month TLPP, was compared to an efficacy performance goal for covered stents

      5/5/25 9:25:00 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance

      First Quarter Highlights† Reported revenue of $355.4 million, up 9.8%Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectivelyGAAP operating margin of 11.5%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.3%, compared to 17.0% in prior year periodGAAP EPS $0.49, up 2.0%Non-GAAP EPS* $0.86, up 14.8%Free cash flow* generation of $19.5 million, down 20.5% † Comparisons above are calculated for the current quarter compared with the first quarter of 2024, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts. * Constant currency revenue; constant cu

      4/24/25 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    Leadership Updates

    Live Leadership Updates

    See more
    • Merit Medical Announces Resignation of President, Joseph Wright

      SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) ("Merit" or the "Company"), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright's resignation, Merit had received notice of allegations regarding his conduct, which Merit's independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Merit's operations or financial performance. Based upon Mr. Wright's resignation, Merit's Board of Directors has re-appointed Fred P. Lampropoulos as Merit's President. ABOUT MERI

      12/16/24 4:00:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Shareholders Elect Silvia M. Perez as New Director

      SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit's Annual Meeting of Shareholders held on May 15, 2024. Merit's shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors. Ms. Perez and Messrs. Lampropoulos and Evans were elected to serve three-year terms. "We are pleased to welcome Silvia Perez as our newest director," said Mr. Lampropoulos, Merit's Chairman and Chief Executive Officer. "Her expertise and proven

      5/16/24 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Executive Leadership Team Update

      Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports "Continued Growth Initiatives" Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr. Wright will be responsible for the oversight of Merit's global commercial, marketing, and manufacturing operations. Mr. Wright has been an instrumental part of the Merit team over the past 19 years. He most recently served as Chief Commercial Officer, where he led the development and expansion of Merit's global commercial activit

      5/15/24 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    Financials

    Live finance-specific insights

    See more
    • Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance

      First Quarter Highlights† Reported revenue of $355.4 million, up 9.8%Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectivelyGAAP operating margin of 11.5%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.3%, compared to 17.0% in prior year periodGAAP EPS $0.49, up 2.0%Non-GAAP EPS* $0.86, up 14.8%Free cash flow* generation of $19.5 million, down 20.5% † Comparisons above are calculated for the current quarter compared with the first quarter of 2024, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts. * Constant currency revenue; constant cu

      4/24/25 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Systems to Announce First Quarter 2025 Results on April 24, 2025

      SOUTH JORDAN, Utah, April 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2025, after the close of the stock market on Thursday, April 24, 2025. Merit plans to hold its investor conference call on the same day (Thursday, April 24, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed us

      4/7/25 5:10:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Issues Fiscal Year 2025 Guidance

      Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4%Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectivelyGAAP operating margin of 10.3%, compared to 10.4% in prior year periodNon-GAAP operating margin* of 19.6%, compared to 16.6% in prior year periodGAAP EPS $0.46, down 2.6%,Non-GAAP EPS* $0.93, up 25.8%, andFree cash flow* generation of $65.3 million, up 18.4% Fiscal Year 2024 Highlights† Reported revenue of $1.357 billion, up 7.9%Constant currency revenue* and constant currency revenue, organic* up 8.5% and up 6.0%, respectivelyGAAP operating margin of 11.5 %, compared to 9.9% in prior yearNon-GAAP opera

      2/25/25 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 14, 2024 - FDA Roundup: June 14, 2024

      For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

      6/14/24 3:54:45 PM ET
      $MMSI
      $BMY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MMSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Merit Medical Systems Inc.

      SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

      11/14/24 11:05:03 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Merit Medical Systems Inc. (Amendment)

      SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

      2/13/24 5:09:38 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Merit Medical Systems Inc. (Amendment)

      SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

      2/12/24 5:32:43 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    SEC Filings

    See more
    • SEC Form 10-Q filed by Merit Medical Systems Inc.

      10-Q - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

      4/24/25 4:24:37 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

      4/24/25 4:20:47 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-K/A filed by Merit Medical Systems Inc.

      10-K/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

      4/14/25 4:08:28 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care